Skip to content
U.S. tariffs on imports could increase the cost of biotechnology operations, threatening innovation that helps patients, according to a survey of biotech firms by […]
BIO survey: Tariffs threaten innovation, access to cures Read More »
The BIO Delegation (pictured from left): Tasuku Kitada (Strand Therapeutics), Adam Roach (BeOne Medicines, formerly Beigene), Jacob Becraft (Strand Therapeutics), John F. Crowley (BIO),
BIO’s mission to Tokyo builds on fruitful cooperation Read More »
Patient perspectives are vital to inform health policy. One agency where such input is particularly crucial is the Centers for Medicare and Medicaid Services
Patient organization engagement of CMS is more important than ever Read More »
Bipartisan legislation reintroduced in the House on Feb. 21 would encourage the development of small-molecule drugs by eliminating the “pill penalty” in the Inflation
EPIC Act introduced to correct IRA’s ‘pill penalty’ Read More »
Beyond inspiring tomorrow’s farmers, FFA (formerly Future Farmers of America) also promotes careers in biotechnology. During FFA Week, the organization is making special efforts
FFA Week promotes careers in biotech for agriculture Read More »
With the new administration bringing new leadership to the Centers for Medicare & Medicaid Services (CMS), one of the most significant healthcare decisions facing
BIO’s message to incoming CMS leadership on improving Part D access for patients Read More »
Legislation introduced last year to ease widespread commercialization of sustainable aviation fuel (SAF) was reintroduced Jan. 16 as one of the early measures proposed
Farm to Fly Act reintroduced in Senate would give SAF wings Read More »
The world needs regulatory reform and greater R&D investment to enable “moonshot” biotech innovations in food production that can meet our growing food needs,
Nobel and World Food Prize holders: Enable biotech innovation for food Read More »
Pharmacy benefit managers (PBMs) make billions in profit while driving up the price of prescription drugs with markups that can exceed 1,000%, according to
FTC’s second report on PBMs blasts drug price markups of 1,000% Read More »
As science progresses, we need parallel progress in making breakthrough treatments widely available, BIO President & CEO John F. Crowley said at a Jan.
BIO CEO urges innovation in access at White House CGT forum Read More »
